Modafinil Improves Symptoms of Attention-Deficit/Hyperactivity Disorder across Subtypes in Children and Adolescents

Journal of Pediatrics

Volumn 152, Issue 3, 2008, Pages

  Biederman, Joseph ^a   Pliszka, Steven R ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD BEHAVIOR; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 38949145320     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.07.052     Document Type: Article

References (31)

1. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
2. Lahey B.B., Applegate B., McBurnett K., Biederman J., Greenhill L., Hynd G.W., et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 151 (1994) 1673-1685
3. Graetz B.W., Sawyer M.G., Hazell P.L., Arney F., and Baghurst P. Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry 40 (2001) 1410-1417
4. Woo B.S., and Rey J.M. The validity of the DSM-IV subtypes of attention-deficit/hyperactivity disorder. Aust N Z J Psychiatry 39 (2005) 344-353
5. Escobar R., Soutullo C., San Sebastian J., Fernandez E., Julian I., and Lahortiga F. Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample. Actas Esp Psiquiatr 33 (2005) 26-32
6. Hoare P., Remschmidt H., Medori R., Ettrich C., Rothenberger A., Santosh P., et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14 (2005) 305-309
7. O'Driscoll G.A., Depatie L., Holahan A.L., Savion-Lemieux T., Barr R.G., Jolicoeur C., et al. Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 1452-1460
8. Scammell T.E., Estabrooke I.V., McCarthy M.T., Chemelli R.M., Yanagisawa M., Miller M.S., et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20 (2000) 8620-8628
9. Lin J.S., Hou Y., and Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 93 (1996) 14128-14133
10. Baumann C.R., and Bassetti C.L. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol 4 (2005) 673-682
11. Konrad K., Neufang S., Hanisch C., Fink G.R., and Herpertz-Dahlmann B. Dysfunctional attentional networks in children with attention deficit/hyperactivity disorder: evidence from an event-related functional magnetic resonance imaging study. Biol Psychiatry 59 (2006) 643-651
12. Zang Y.F., Jin Z., Weng X.C., Zhang L., Zeng Y.W., Yang L., et al. Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality. Brain Dev 27 (2005) 544-550
13. Swanson J.M., Greenhill L.L., Lopez F.A., Sedillo A., Earl C.Q., Jiang J., et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 67 (2006) 137-147
14. Biederman J., Swanson J.M., Wigal S.B., Kratochvil C.J., Boellner S.W., Earl C.Q., et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116 (2005) e777-e784
15. Greenhill L.L., Biederman J., Boellner S.W., Rugino T.A., Sangal R.B., Earl C.Q., et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 503-511
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (1994), American Psychiatric Association, Washington, DC
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM) 76-338 (1976), National Institute of Mental Health, Rockville, MD
18. DuPaul G.J., Power T.J., Anastopoulos A.D., and Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation (1998), Guilford Press, New York
19. Conners C.K. Conners' Parent Rating Scales-Revised: Short Form (CPRS-R:S) (1997), Multi-Health Systems, Tonawanda, NY
20. Booth J.H. Conners' Rating Scales-revised. Gale Encyclopedia of Mental Disorders (2003), The Gale Group, Inc, Detroit, MI. http://www.healthline.com/galecontent/conners-rating-scales-revised Available at: http://www.healthline.com/galecontent/conners-rating-scales-revised. Accessed May 15, 2007
21. Wigal S.B., Biederman J., Swanson J.M., Yang R., and Greenhill L.L. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Primary Care Companion J Clin Psychiatry 8 (2006) 352-360
22. Gaub M., and Carlson C.L. Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J Abnorm Child Psychol 25 (1997) 103-111
23. Faraone S.V., Biederman J., Weber W., and Russell R.L. Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry 37 (1998) 185-193
24. Nolan E.E., Gadow K.D., and Sprafkin J. Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. J Am Acad Child Adolesc Psychiatry 40 (2001) 241-249
25. Baumgaertel A., Wolraich M.L., and Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry 34 (1995) 629-638
26. Eiraldi R.B., Power T.J., and Nezu C.M. Patterns of comorbidity associated with subtypes of attention-deficit/hyperactivity disorder among 6- to 12-year-old children. J Am Acad Child Adolesc Psychiatry 36 (1997) 503-514
27. Levy F., Hay D.A., Bennett K.S., and McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 44 (2005) 368-376
28. Wolraich M.L., Hannah J.N., Pinnock T.Y., Baumgaertel A., and Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 35 (1996) 319-324
29. Spencer T.J., Abikoff H.B., Connor D.F., Biederman J., Pliszka S.R., Boellner S., et al. Efficacy and safety of mixed amphetamine salts extended-release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 28 (2006) 402-418
30. Aman M.G., Binder C., and Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14 (2004) 243-254
31. Kopecky H., Chang H.T., Klorman R., Thatcher J.E., and Borgstedt A.D. Performance and private speech of children with attention-deficit/hyperactivity disorder while taking the Tower of Hanoi test: effects of depth of search, diagnostic subtype, and methylphenidate. J Abnorm Child Psychol 33 (2005) 625-638